CHIMERIX Trademark

Trademark Overview

On Thursday, March 22, 2007, a trademark application was filed for CHIMERIX with the United States Patent and Trademark Office. The USPTO has given the CHIMERIX trademark a serial number of 77137575. The federal status of this trademark filing is REGISTERED AND RENEWED as of Monday, September 25, 2017. This trademark is owned by Chimerix, Inc.. The CHIMERIX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical drug development services
chimerix

General Information

Serial Number77137575
Word MarkCHIMERIX
Filing DateThursday, March 22, 2007
Status800 - REGISTERED AND RENEWED
Status DateMonday, September 25, 2017
Registration Number3317018
Registration DateTuesday, October 23, 2007
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 7, 2007

Trademark Statements

Goods and ServicesPharmaceutical drug development services

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, March 26, 2007
Primary Code042
First Use Anywhere DateWednesday, April 7, 2004
First Use In Commerce DateWednesday, April 7, 2004

Trademark Owner History

Party NameChimerix, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressDURHAM, NC 27713
Party NameChimerix, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDurham, NC 27713
Party NameChimerix, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDurham, NC 27713

Trademark Events

Event DateEvent Description
Wednesday, October 23, 2013REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
Monday, March 26, 2007NEW APPLICATION ENTERED
Tuesday, April 24, 2007ASSIGNED TO EXAMINER
Tuesday, April 24, 2007APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 11, 2007ASSIGNED TO LIE
Friday, May 11, 2007LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, July 18, 2007NOTICE OF PUBLICATION
Tuesday, August 7, 2007PUBLISHED FOR OPPOSITION
Tuesday, October 23, 2007REGISTERED-PRINCIPAL REGISTER
Wednesday, October 23, 2013TEAS SECTION 8 & 15 RECEIVED
Monday, November 11, 2013REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Friday, August 2, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, November 11, 2013CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, November 11, 2013NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Sunday, October 23, 2016COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Thursday, August 17, 2017TEAS SECTION 8 & 9 RECEIVED
Monday, September 25, 2017CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, September 25, 2017REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Monday, September 25, 2017REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Monday, September 25, 2017NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Friday, August 2, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, September 20, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 31, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 31, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, September 20, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, September 20, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, September 20, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, September 20, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, September 20, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, June 20, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, June 20, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, June 20, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, June 20, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED

Related Keywords

chimerix services development drug pharmaceutical